Drug Profile
Entrectinib - Roche
Alternative Names: Entrectinib - Ignyta; NMS-E628; RG 6268; Rozlytrek; RXDX-101; TrkA/TrkB/TrkC/ROS1/ALK inhibitor - RocheLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Developer Alliance for Clinical Trials in Oncology; Chugai Biopharmaceuticals; Genentech; National Cancer Institute (USA); Roche; University of California at San Francisco
- Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Indazoles; Piperazines; Pyrans; Small molecules; Tumour-agnostic therapies
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Solid tumours
- Phase II Brain metastases; Malignant melanoma
- Phase I/II Uveal melanoma
- No development reported Acute myeloid leukaemia
Most Recent Events
- 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
- 20 Oct 2023 Pooled efficacy and adverse events data from the phase I STARTRK-1, phase I/II ALKA-372-001, and phase II STARTRK-2, TAPISTRY trial in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 11 Oct 2023 Efficacy and adverse events data from the phase II STARTRK-2 trial in Solid tumors presented at International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)